OHSU
Return to Listing

2 result(s) for RITUXAN

PI Name Protocol # Title
Stephen Spurgeon IRB00009556 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
Andy Chen IRB00010274 A Phase Ib Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of DCDS4501A in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with B-Cell Non-Hodgkin’s Lymphoma
 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080
 

You may qualify for additional trials within our Phase 1 Program